Providence and GRAIL Expand Partnership to Increase Access to Galleri® Multi-Cancer Early Detection Screening
Providence and GRAIL, LLC have expanded their partnership to offer the Galleri multi-cancer early detection (MCED) test across Providence's 52 hospitals and 900 clinics in seven states. This test can detect signals from over 50 cancer types, enhancing early detection capabilities, particularly for hard-to-detect cancers. The Galleri test was previously available in California, Washington, and Oregon, and is now also offered in Alaska, Montana, New Mexico, and Texas. This expansion aims to improve patient outcomes and support ongoing cancer research and diagnostics.
- Expansion of partnership enables broader access to Galleri MCED test.
- Galleri can detect signals from over 50 cancer types, improving early detection.
- Supports ongoing research and innovation in cancer diagnostics.
- None.
Through the partnership, eligible patients at Providence’s 52 hospitals and 900 clinics across seven states will have access to GRAIL’s Galleri® multi-cancer early detection (MCED) test, as part of a comprehensive range of health services. In clinical studies, Galleri has demonstrated the ability to detect signals across more than 50 types of cancers — more than 45 of which lack recommended screening tests today. When a cancer signal is detected, Galleri can help ascertain where in the body the cancer is located with high accuracy, all from a single blood draw. In addition to broadening access to MCED testing, the expansion supports innovative diagnostics and genomics research aimed at improving cancer screening and treatment.
“Providence is committed to collaborations that provide individuals with the best evidence-based care including advancements like early cancer screenings that can improve patient outcomes,” said
According to the
“One of the best ways to improve cancer outcomes is to find cancer earlier, when it is easier to treat and the likelihood of survival is higher,” said
Providence was the first health system in the nation to offer the MCED blood test as a complement to recommended cancer screenings to advance the science and delivery of cancer care. Providence and GRAIL previously announced an initial partnership in
About Providence
Providence is a national, not-for-profit health system comprising a diverse family of organizations and driven by a belief that health is a human right. With 52 hospitals, over 900 physician clinics, senior services, supportive housing, and many other health and educational services, the health system and its partners employ more than 120,000 caregivers serving communities across seven states—Alaska,
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in
For more information, visit grail.com.
About Galleri®
The earlier that cancer is detected, the higher the chance of successful outcomes. The Galleri multi-cancer early detection test can detect a shared cancer signal across more than 50 types of cancer, as defined by the
For more information about Galleri, visit galleri.com.
Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “Cancer Signal Not Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory/Test Information
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the
View source version on businesswire.com: https://www.businesswire.com/news/home/20230404005455/en/
For GRAIL
Corporate Communications
pr@grail.com
Investor Relations
ir@grail.com
For Providence
Samantha.Desmarais@Providence.org
Source:
FAQ
What is the purpose of the partnership between Providence and GRAIL, LLC?
What states will provide access to the Galleri test after the expansion?
How many types of cancer can the Galleri test detect?
When was the initial partnership between Providence and GRAIL established?
What are the implications of the Galleri test for cancer detection?